长春高新：子公司GenSci145片注册临床试验申请获得受理

Core Viewpoint - Changchun High-tech announced that its subsidiary, Gensci Pharmaceutical, has received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of GenSci145 tablets, a new selective PI3Kα inhibitor developed by Gensci [1] Group 1 - Gensci145 tablets have demonstrated strong selective inhibitory activity against various hotspot mutations in the PIK3CA helical and kinase domains during preclinical studies [1] - The drug has shown clear efficacy and good safety characteristics in animal models [1]